Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DMP10
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DMP10 (also referred to as [68Ga]dmp10) is a gallium-68 labeled multicyclic peptide radiotracer designed for positron emission tomography (PET) imaging to noninvasively assess programmed death-ligand 1 (PD-L1) expression in solid tumors. The targeting moiety, dmp10, is a disulfide-rich multicyclic peptide (~3 kDa) engineered via disulfide-directed library design and iterative directed evolution to bind PD-L1 with picomolar affinity. By binding to PD-L1, 68Ga-DMP10 enables whole-body PET/CT imaging to evaluate PD-L1 expression, helping to overcome the limitations of spatial and temporal heterogeneity associated with traditional immunohistochemistry (IHC) biopsies. It is being developed as a diagnostic biomarker and potential theranostic platform for solid tumors, with Peking Union Medical College Hospital and Xiamen University involved in its development.
- Other names
- 68Ga-labeled dmp10[68Ga]Ga-dmp10[68Ga]dmp10
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on 68Ga-DMP10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DMP10.